(S)-2-[3-(2-methoxymethylthiazol-4-ylmethyl)-2,4-dioxoimidazolidin-1-yl]-3-methylbutyric acid | 911067-14-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-2-[3-(2-methoxymethylthiazol-4-ylmethyl)-2,4-dioxoimidazolidin-1-yl]-3-methylbutyric acid
• CAS: 911067-14-6
• 化学式: C₁₄H₁₉N₃O₅S
• 分子量: 341.388
• InChiKey: PHLNHINITZSSOU-LBPRGKRZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.16
• 重原子数：
  23.0
• 可旋转键数：
  7.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  100.04
• 氢给体数：
  1.0
• 氢受体数：
  6.0

反应信息

• 作为反应物：
  描述：

  N-((2R,3S)-3-amino-2-hydroxy-4-phenylbutyl)-4-(E-hydroxyiminomethyl)-N-(isobutyl)benzenesulfonamide 、 (S)-2-[3-(2-methoxymethylthiazol-4-ylmethyl)-2,4-dioxoimidazolidin-1-yl]-3-methylbutyric acid 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N-甲基吗啉 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 17.0h， 以50%的产率得到(2S)-N-{(1S,2R)-1-benzyl-2-hydroxy-3-[({4-[(E)-(hydroxyimino)methyl]phenyl}sulfonyl)(isobutyl)amino]propyl}-2-(3-{[2-(methoxymethyl)-1,3-thiazol-4-yl]methyl}-2,4-dioxo-1-imidazolidinyl)-3-methylbutanamide
  参考文献：
  名称：

  HIV protease inhibiting compounds

  摘要：

  公开了一种具有以下公式的化合物，作为HIV蛋白酶抑制剂。还公开了抑制HIV感染的方法和组合物。

  公开号：

  US20110003827A1
• 作为产物：
  描述：

  (S)-2-[3-(2-methoxymethylthiazol-4-ylmethyl)-2,4-dioxoimidazolidin-1-yl]-3-methylbutyric acid tert-butyl ester 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 (S)-2-[3-(2-methoxymethylthiazol-4-ylmethyl)-2,4-dioxoimidazolidin-1-yl]-3-methylbutyric acid
  参考文献：
  名称：

  Discovery of imidazolidine-2,4-dione-linked HIV protease inhibitors with activity against lopinavir-resistant mutant HIV

  摘要：

  A new series of HIV protease inhibitors has been designed and synthesized based on the combination of the (R)-(hydroxyethylamino)sulfonamide isostere and the cyclic urea component of lopinavir. The series was optimized by replacing the 6-membered cyclic urea linker with an imidazolidine-2,4-dione which readily underwent N-alkylation to incorporate various methylene-linked heterocycle groups that bind favorably in site 3 of HIV protease. Significant improvements compared to lopinavir were seen in cell culture activity versus wild-type virus (pNL4-3) and the lopinavir-resistant mutant virus A17 (generated by in vitro serial passage of HIV-1 (pNL4-3) in NIT-4 cells). Select imidazolidine-2,4-dione containing Pis were also more effective at inhibiting highly resistant patient isolates Pt1 and Pt2 than lopinavir. Pharmacokinetic data collected for compounds in this series varied considerably when coadministered orally in the rat with an equal amount of ritonavir (5 mg/kg each). The AUC values ranged from 0.144 to 12.33 mu g h/mL. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2006.05.063